Table 3: Targeted therapies evaluated in clinical trials for thyroid cancer.

DrugVEGFR1VEGFR2VEGFR3RETBRAFOtherResponse; PFSCitation

AxitinibXXX31% PR; 18 mos (MTC included)Cohen et al. [91, 99]

MotesanibXXXX14% PR; 9 mosSherman et al. [97]

SorafenibXXXX13–32% PR; PFS 10–21 mosKloos et al. [86], Gupta-Abramson et al. [87], Cabanillas et al. [88]

SunitinibXXXX28% CR + PR; TTP 13 mos Carr et al. [93]

PazopanibXXXX49% PR; PFS 12 mos Bible et al. [94]

LenvatinibXXXXFGFR50% PR; PFS 13 mosSherman et al. [105]

CabozantinibXXXc-MET53% PR; PFS n/a Cabanillas et al. [101]

PR: partial response, SD: stable disease, TTP: time to progression, PFS: progression-free surivival, n/a: not available, and mos: months.